Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT. Zhu AX, et al. Among authors: furuse j. JAMA. 2014 Jul 2;312(1):57-67. doi: 10.1001/jama.2014.7189. JAMA. 2014. PMID: 25058218 Clinical Trial.
Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version).
Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, Furuse J, Nakamura K, Makuuchi M; Liver Cancer Study Group of Japan (Committee for Response Evaluation Criteria in Cancer of the Liver, Liver Cancer Study Group of Japan). Kudo M, et al. Among authors: furuse j. Hepatol Res. 2010 Jul;40(7):686-92. doi: 10.1111/j.1872-034X.2010.00674.x. Hepatol Res. 2010. PMID: 20633194
Liver Cancer Working Group report.
Kudo M, Han KH, Kokudo N, Cheng AL, Choi BI, Furuse J, Izumi N, Park JW, Poon RT, Sakamoto M. Kudo M, et al. Among authors: furuse j. Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i19-27. doi: 10.1093/jjco/hyq123. Jpn J Clin Oncol. 2010. PMID: 20870915
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Kudo M, et al. Among authors: furuse j. Eur J Cancer. 2011 Sep;47(14):2117-27. doi: 10.1016/j.ejca.2011.05.007. Eur J Cancer. 2011. PMID: 21664811 Clinical Trial.
Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update.
Kaneko S, Furuse J, Kudo M, Ikeda K, Honda M, Nakamoto Y, Onchi M, Shiota G, Yokosuka O, Sakaida I, Takehara T, Ueno Y, Hiroishi K, Nishiguchi S, Moriwaki H, Yamamoto K, Sata M, Obi S, Miyayama S, Imai Y. Kaneko S, et al. Among authors: furuse j. Hepatol Res. 2012 Jun;42(6):523-42. doi: 10.1111/j.1872-034X.2012.00981.x. Hepatol Res. 2012. PMID: 22568457
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.
Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA. Lencioni R, et al. Among authors: furuse j. Int J Clin Pract. 2012 Jul;66(7):675-83. doi: 10.1111/j.1742-1241.2012.02940.x. Int J Clin Pract. 2012. PMID: 22698419 Free article.
363 results